ClinicalTrials.gg
Not yet recruitingNCT07623681R/R T-ALL/LBLUpdated Jun 3, 2026

Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

A Phase 1 interventional study of T cell injection targeting CD7 chimeric antigen receptor in CD7+ T-ALL/LBL, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
41st of 50
12 · median 30
Started
2026
with 4 others
Phase 1
22 of 51
8 open now
Primary completion
2026-06
later than 7 of 27 live
Registered
50th of 51
by date
Lead sponsor
4 of 51
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 41st largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 7 of the 27 other live ones, and was the 50th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population.

Secondary objectives include evaluating the pharmacokinetics/pharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.

Read the detailed description

In the dose-escalation phase of this phase I trial, the conventional 3+3 design is adopted with three dose cohorts. The starting dose is 1×10\^6 CAR-T cells/kg, followed by incremental doses of 2×10\^6CAR-T cells/kg and 4×10\^6CAR-T cells/kg. A total of 9 to 18 pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma will be enrolled.

In the first and second cohorts, subsequent participants may receive treatment after the prior subject completes a minimum 14-day safety observation period. For the third cohort, dosing of the next subject can proceed only after a 28-day safety monitoring period for the previous participant.

After the final subject in each cohort finishes the 28-day dose-limiting toxicity (DLT) assessment post single administration, enrollment for the next cohort can commence upon approval from the Safety Review Committee based on clinical safety data.

If one DLT occurs among 3 subjects in a cohort, 3 additional participants will be enrolled in the same cohort, bringing the total assessed subjects to 6. No further dose escalation will be conducted if one or more DLTs are observed in the supplementary subjects. Enrollment will then resume at the preceding lower dose level with another 3 subjects for DLT evaluation.

During the dose expansion phase of the phase I trial, the Safety Review Committee will review available safety, efficacy, pharmacokinetic and immunogenicity data to comprehensively determine the recommended phase II dose. At least 3 additional participants will be enrolled at this dose level. No dosing interval restriction or DLT assessment is required for expanded enrollment, so as to further confirm the preliminary efficacy and safety of the recommended phase II dose.

03

Conditions studied

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Aged from 3 to 18 years (inclusive), with no restriction on gender. (2) Expected survival time ≥ 3 months. (3) At screening, Performance Status score (for subjects aged ≥ 16 years) or Lansky Performance Score (for subjects aged \< 16 years) > 60 points (see Appendix 4).

    (4) Diagnosed with T-ALL or T-LBL (including ETP-ALL and ETP-LBL) by local laboratories based on the classification criteria of WHO Classification of Haematolymphoid Tumours, 5th Edition: Lymphoid Neoplasms, confirmed via MICM classification (morphology, immunology, cytogenetics and molecular genetics), and/or pathological and imaging examinations.

For subjects diagnosed with T-LBL: bone marrow smear shows blasts between 5% (inclusive) and 20% (exclusive), or focal infiltration is observed on bone marrow indicating bone marrow involvement of T-LBL.

(5) Subjects with disease after failure of standard treatment or without available effective treatment options:

① Refractory disease: Failure to achieve remission after completion of at least 2 cycles of standard induction chemotherapy*.

② Relapsed disease: New extramedullary lesions or bone marrow recurrence occurring in subjects who have achieved complete remission (CR).

Early relapse (\< 12 months) after complete remission; Late relapse (≥ 12 months) after complete remission with no response to one cycle of standard induction chemotherapy*.

Definition of bone marrow recurrence: If the percentage of blasts/immature lymphocytes in bone marrow smear is ≥ 5% and \< 20%, evidence of molecular recurrence is required. In the absence of molecular recurrence evidence, at least two consecutive test results (both ≥ 5%) are required.

  • Failure to achieve remission after treatment with two or more regimens*.

    • Two or more episodes of relapse.

      • Relapse after hematopoietic stem cell transplantation. * Remission criteria: CR and CRi for T-ALL; CR and PR for T-LBL. (6) At screening: ① Abnormal tumor cells are detected in bone marrow and/or peripheral blood by multi-color flow cytometry, regardless of the presence or absence of extramedullary lesions on imaging. Abnormal tumor cells in bone marrow must be CD7-positive; abnormal tumor cells in peripheral blood must be CD7-positive, CD4-negative and CD8-negative.

        • No abnormal tumor cells are detected in bone marrow and/or peripheral blood by multi-color flow cytometry, and imaging shows only extramedullary lesions (e.g. lymphadenopathy). Immunohistochemistry of lesion specimens must confirm CD7 positivity with a CD7 positive rate ≥ 70%.

          (7) For subjects with only extramedullary lesions: lesions shall be evaluable (by PET-CT) or measurable (by contrast-enhanced CT) per the 2014 Lugano Criteria for efficacy assessment specified in Appendix 5.

          (8) Liver, renal, cardiac and pulmonary function shall meet the following criteria:

          ① Total ≤ 2 × ; and AST ≤ 2.5 × ULN. If ALT/AST elevation is judged by the investigator to be caused by the underlying disease (e.g. liver infiltration or biliary obstruction), the upper limit may be extended to ≤ 5 × ULN. For subjects diagnosed with Gilbert's syndrome, total bilirubin ≤ 3.0 × ULN with direct bilirubin ≤ 1.5 × ULN.

        • Creatinine ≤ 1.5 × ULN.
  • (LVEF) ≥ 45%. ④ Oxygen saturation > 91%. (9) The subject and/or legal guardian fully understands this trial, has signed the form, and is willing and able to comply with scheduled visits, treatment regimens, laboratory tests and all other study requirements specified in the study schedule.

Exclusion criteria

Exclusion Criteria:

  • (1) Patients judged by the investigator to require long-term use of at screening.

    (2) Cerebrovascular accident or seizure occurring within 6 months prior to signing the form.

    (3) Uncontrolled (GvHD) or ongoing requirement for systemic treatment for GvHD.

    (4) History of other (other than T-ALL/LBL) within 5 years prior to screening, except for cured carcinoma in situ.

    (5) Subjects with positive surface antigen (HBsAg) and abnormal peripheral blood hepatitis B virus (HBV) DNA titer; positive hepatitis B core antibody (HBcAb) with abnormal peripheral blood HBV DNA titer; positive virus (HCV) antibody coupled with positive peripheral blood HCV RNA; positive (HIV) antibody; positive cytomegalovirus (CMV) DNA; positive syphilis serology; positive Epstein-Barr virus (EBV) DNA.

    (6) Severe cardiac diseases, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure ( [NYHA] Class ≥ III), and severe arrhythmia.

    (7) Unstable systemic diseases as assessed by the investigator, including but not limited to severe hepatic, renal or metabolic diseases requiring medical treatment.

    (8) Presence of chronic progressive neurological diseases. (9) Patients with unresolved acute toxicities from prior treatments. (10) Active or uncontrolled infections requiring systemic therapy (excluding mild genitourinary tract infections and upper respiratory tract infections).

    (11) Female subjects of who plan to become pregnant within 2 years after cell infusion; male subjects whose partners plan to become pregnant within 2 years after cell infusion.

    (12) Subjects who have received CAR-T therapy or other genetically modified cell therapies prior to screening.

    (13) Participation in another clinical trial within 1 month prior to screening (calculated from the last administration of unapproved products).

    (14) Evidence of central nervous system (CNS) involvement identified at screening.

    (15) Any other conditions deemed ineligible for enrollment by the investigator.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    T cell injection targeting CD7 chimeric antigen receptor

    PA3-17 injection The subjects,who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1.0\*10\^6,2.0\*10\^6 and 4.0\*10\^6 CAR-T/kg groups in order of sequence.And the subjects will be administered once.

    Biological: T cell injection targeting CD7 chimeric antigen receptor

Interventions

  • PA3-17 injection The subjects,who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1.0\*10\^6,2.0\*10\^6 and 4.0\*10\^6 CAR-T/kg groups in order of sequence.And the subjects will be administered once.

06

What researchers measure

Primary outcomes

  1. MTD

    Maximum tolerated dose

    Time frame: About 2 years

  2. DLT

    Dose limiting toxicity

    Time frame: About 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2026, 0 months later.

Of 42 phase 1 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 76. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartEst.
Jun 10, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 30, 2028
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623681
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 10, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Jun 3, 2026

Study contacts

Xiaofan Zhu, doctor
Contact
Zhuxiaofan@ihcams.ac.cn
13752090418
Xiuli Ju, Doctor
principal investigator · Qilu Hospital of Shandong University
Xiaojun Xu, Doctor
principal investigator · The Children's Hospital of Zhejiang University School of Medicine
Fen Zhou, Doctor
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD7 CAR T Cells PA3-17

Start the discussion